What percentage of the cost of Osimertinib can be reimbursed by medical insurance?

Osimertinib, also known as Osimertinib, is a third-generation EGFR-TKI targeted drug that is widely used in patients with non-small cell lung cancer who have positive EGFR gene mutations. The drug has been successfully launched in my country and has been included in the national medical insurance catalog, which has greatly reduced the financial burden on patients. After medical insurance reimbursement, the actual expenses paid by patients are significantly reduced, but the specific reimbursement ratio varies depending on regional policies and patients’ medical insurance types (urban employees, urban and rural residents, etc.).

At present, the medical insurance payment for osimertinib is generally treated as a Class A drug, and in most areas it can reimburse about 70%-80% of the cost. Taking Osimertinib80mg Calculated based on a 70% reimbursement ratio, the patient's monthly out-of-pocket expense is approximately between 1,500 yuan and 1,800 yuan. If the patient has critical illness insurance or a secondary reimbursement mechanism, the actual expenditure can be further reduced. For specific reimbursement ratios, it is recommended that patients consult with the medical insurance bureau or hospital pharmacy in their city to obtain the most accurate local policy information.

In addition to the original drug, there are also generic osimertinib drugs officially launched overseas, such as Laos and Bangladesh. These generic drugs are consistent with the original drugs in terms of drug ingredients, dosage, and dosage methods, and have been approved by the local drug regulatory authorities, so their quality and efficacy are relatively guaranteed. In terms of price, the selling price of these generic drugs is much lower than that of domestic original drugs. Generally, the price of 80 mg × 30 tablets is several hundred yuan. It is an economically feasible option for patients who are not covered by medical insurance or who have difficulty affording original drugs.

It should be noted that generic drugs have not yet been registered and marketed in my country, so they cannot be reimbursed through domestic medical insurance and must be obtained through compliant overseas channels. When choosing generic drugs, patients should ensure that the drugs come from regular sources and avoid buying fake and shoddy products. With the support of medical insurance policies, most domestic patients can first choose original research drugs for treatment, and use the drugs under the guidance of doctors to ensure the standardization and safety of treatment. For special situations where you cannot afford the high drug costs or are not covered by medical insurance, you can also consider using overseas generic drugs under the guidance of professionals.

Reference materials:https://go.drugbank.com/drugs/DB09330